The company’s radio-immunotherapy drug candidate is an armed-antibody drug being  a toxin-modified antibody and has been shown to kill only the cancer cells in models using various cancer cells. The drug binds to only cells with HAAH on the surface (cancer cells) and is then taken into the cells where the toxin is released killing the cancer cells; toxin alone cannot get into the cells. A monoclonal antibody-based immunotherapy drug under development by Panacea uses a beta-emitting radionuclide attached to PAN-622.  The antibody-radionuclide conjugate binds to the tumor, is then internalized, and consequently, the beta-emitting particle kills the cancer cells and only the cancer cells.  Panacea is currently testing this drug in preclinical studies and expects to start its clinical trial in 2017.